Financial Performance - Operating revenue for Q1 2022 was RMB 146.39 million, representing a growth of 24.25% year-over-year[16]. - Net profit attributable to shareholders for Q1 2022 was RMB 21.00 million, a 35.11% increase compared to the same period last year[16]. - The company's overall gross margin improved to 80.53%, up 2.54 percentage points from 77.99% in the previous year[17]. - Cash flow from operating activities for Q1 2022 was RMB 41.67 million, a significant increase of 843.29% year-over-year[18]. - The net profit after deducting non-recurring gains and losses was RMB 16.85 million, reflecting a growth of 16.91% year-over-year[16]. - Total revenue for Q1 2022 reached ¥146,385,175.70, an increase from ¥117,814,952.19 in Q1 2021, representing a growth of approximately 24.3%[95]. - The net profit for Q1 2022 was ¥21,002,890.48, representing a 35% increase from ¥15,545,169.76 in Q1 2021[97]. - The company's total profit for Q1 2022 was ¥25,256,081.75, compared to ¥18,908,857.19 in Q1 2021, marking a 33% increase[96]. - The operating profit for Q1 2022 was ¥25,293,248.56, an increase of 32% from ¥19,069,602.22 in Q1 2021[96]. - The total comprehensive income for Q1 2022 was ¥21,002,890.48, compared to ¥15,545,169.76 in Q1 2021, showing a growth of 35%[97]. Assets and Liabilities - Total assets as of March 31, 2022, reached RMB 886.63 million, an increase of 5.80% compared to the end of 2021[16]. - Total liabilities rose to ¥169,516,543.83, up from ¥146,568,023.42, indicating an increase of approximately 15.6%[89]. - Current liabilities totaled ¥138,626,755.19, compared to ¥115,446,207.16, marking an increase of around 19.9%[89]. - Non-current liabilities decreased slightly to ¥30,889,788.64 from ¥31,121,816.26, showing a decline of about 0.7%[89]. - Shareholders' equity increased to ¥717,114,651.10 from ¥691,454,933.84, reflecting a growth of approximately 3.7%[89]. Shareholder Information - The total number of unrestricted shares increased from 19,847,926 to 43,878,944, representing a growth from 30.40% to 67.21% of total shares[24]. - The total number of restricted shares decreased from 45,438,074 to 21,407,056, changing from 69.60% to 32.79% of total shares[24]. - The largest shareholder, Li Yong'an, holds 6,761,216 shares, accounting for 10.36% of total shares[24]. - The company has 6,494 shareholders as of the end of the reporting period[24]. Cash Flow and Investments - Cash and cash equivalents were reported at ¥410,878,051.29, up from ¥368,291,060.02 at the end of 2021, indicating an increase of about 11.6%[87]. - Cash flow from operating activities for Q1 2022 was CNY 41,667,684.10, a significant increase from CNY 4,417,269.24 in Q1 2021, representing a growth of approximately 841%[101]. - Cash inflow from investment activities in Q1 2022 totaled CNY 31,466,927.14, a substantial rise from CNY 6,755,540.21 in Q1 2021, marking an increase of around 366%[102]. - The ending cash and cash equivalents balance for Q1 2022 was CNY 408,813,822.65, up from CNY 362,587,768.60 in Q1 2021, reflecting an increase of about 13%[102]. Research and Development - Research and development expenses increased to ¥14,753,104.23 in Q1 2022, up from ¥11,845,387.19 in Q1 2021, reflecting a growth of 24%[96]. - The company emphasizes the importance of R&D investment and market expansion to enhance competitiveness and sustainable profitability, focusing on endocrine therapy drug development[50]. Corporate Governance and Compliance - The company has not faced any litigation or arbitration matters during the reporting period[28]. - The company has committed to avoiding any business activities that directly compete with its existing products, ensuring no conflicts of interest with its controlling shareholders[78]. - The controlling shareholders have pledged to minimize and regulate related party transactions, ensuring that any unavoidable transactions adhere to market principles and fair pricing[80]. - The company will strictly fulfill all public commitments made during this issuance and actively accept social supervision[72]. Profit Distribution and Shareholder Returns - The company has committed to a profit distribution policy that ensures cash dividends will not be less than 20% of the distributable profits for the year, with a cumulative cash distribution of at least 60% of the average annual distributable profits over the last three years[56]. - The company plans to review its shareholder dividend return plan at least every three years after listing on the selected tier, considering feedback from shareholders, independent directors, and external supervisors[57]. - The company has a strong profitability and capital management capability, allowing it to provide stable and reasonable returns to shareholders[57]. - The company emphasizes a cash dividend as the primary method of profit distribution, maintaining a focus on shareholder returns[56]. Future Commitments and Plans - The company plans to invest up to 100 million RMB of idle funds in low-risk financial products within 12 months to enhance fund utilization efficiency[31]. - The company intends to use up to 284.19 million RMB of idle raised funds to purchase principal-protected bank products, also within a 12-month period[32]. - The company signed an agreement to acquire a 55% stake in Tongli Haiyuan Biotechnology Co., Ltd. for 155 million RMB, which was approved by the shareholders' meeting[33].
德源药业(832735) - 2022 Q1 - 季度财报